GlobeNewswire
-
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
09/03/2026 -
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
09/03/2026 -
SS Innovations Announces Completion of an $18.6 Million Private Placement to Support Growth Initiatives
09/03/2026 -
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
09/03/2026 -
Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
09/03/2026 -
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
09/03/2026 -
SRx Health Solutions Launches EventHorizonIQ Subscription for Individual and Institutional Traders
09/03/2026 -
NovelMed Therapeutics Announces Regulatory Clearance for Subcutaneous Ruxoprubart and Reports Positive Phase II Intravenous Monotherapy Results in PNH
09/03/2026 -
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼
09/03/2026 -
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
09/03/2026 -
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
09/03/2026 -
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
09/03/2026 -
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
09/03/2026 -
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
09/03/2026 -
Claritas Neuroclould™ Receives Approval from Brazil Regulator ANVISA to Market the Software Device for Brain Imaging Analysis, Localisation and Quantification in PET, SPECT and MRI
09/03/2026 -
New paper in Frontiers in Medicine reveals first reliable biomarker test for early kidney transplant rejection detection in living-donor recipients
09/03/2026 -
kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics
09/03/2026 -
TME Pharma extends financial runway to over 12 months
09/03/2026 -
TME PHARMA PROLONGE SA CAPACITÉ FINANCIÈRE À PLUS DE 12 MOIS
09/03/2026
Pages